Trial Profile
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Mitoxantrone (Primary) ; Sorafenib (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results evaluating the efficacy of addition of sorafenib to CLAG-M (CLAGM+S) in adults with newly diagnosed Acute Myeloid Leukemia or other high-grade myeloid neoplasms presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 07 Feb 2022 Planned End Date changed from 31 Jan 2023 to 3 Feb 2027.